表紙
市場調査レポート

嚢胞性線維症:パイプライン製品の分析

Cystic Fibrosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232829
出版日 ページ情報 英文 406 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
嚢胞性線維症:パイプライン製品の分析 Cystic Fibrosis - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 406 Pages
概要

嚢胞性線維症は、粘液および発汗、消化液を生成する細胞に作用する遺伝性疾患です。その症状は喘鳴、息切れ、度重なる肺感染症、鼻腔の炎症、重度の便秘などがあります。嚢胞性線維症に罹患には遺伝的要因、人種(北欧圏の白人に多い)が深くかかわっていると言われています。治療には抗菌薬、濃性粘液の分解薬、気管支拡張薬、経口の膵酵素剤などを利用します。

当レポートでは、嚢胞性線維症治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

嚢胞性線維症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

嚢胞性線維症:企業で開発中の治療薬

嚢胞性線維症:大学/機関で研究中の治療薬

嚢胞性線維症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

嚢胞性線維症:企業で開発中の製品

嚢胞性線維症:大学/機関で研究中の製品

嚢胞性線維症の治療薬開発に従事している企業

  • Actelion Ltd
  • Akari Therapeutics, Plc
  • Alaxia SAS
  • AlgiPharma AS
  • AmpliPhi Biosciences Corporation
  • Arcturus Therapeutics, Inc
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Calista Therapeutics, Inc.
  • Carolus Therapeutics, Inc.
  • Celtaxsys, Inc.
  • Chiesi Farmaceutici SpA
  • Cilian AG
  • Concert Pharmaceuticals, Inc.
  • Corbus pharmaceuticals, Inc.
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals, Inc.
  • DiscoveryBiomed, Inc.
  • Editas Medicine, Inc.
  • Errant Gene Therapeutics, LLC
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • Grupo Praxis Pharmaceutical SA
  • Horizon Pharma Plc
  • Insmed Incorporated
  • Invion Limited
  • JHL Biotech, Inc.
  • Kamada Ltd.
  • La Jolla Pharmaceutical Company
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Microbion Corporation
  • Mucokinetica Ltd.
  • NanoBio Corporation
  • Nivalis Therapeutics, Inc.
  • Nostrum Pharmaceuticals, LLC
  • Novabiotics Limited
  • Novartis AG
  • OSE Pharma SA
  • Parion Sciences, Inc.
  • Pfizer Inc.
  • Pharmaxis Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Polyphor Ltd.
  • Progenra, Inc.
  • ProMetic Life Sciences Inc.
  • ProQR Therapeutics N.V.
  • Protalix BioTherapeutics, Inc.
  • Proteostasis Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Pulmatrix, Inc.
  • Raptor Pharmaceutical Corp.
  • ReveraGen BioPharma, Inc.
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Shionogi & Co., Ltd.
  • Shire Plc
  • Synovo GmbH
  • TGV-Laboratories
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Incorporated
  • Xenetic Biosciences (UK) Limited
  • Zambon Company S.p.A.

嚢胞性線維症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (ammonium chloride + citric acid + sodium citrate)
  • (fosfomycin + tobramycin)
  • (ivacaftor + tezacaftor)
  • ABPA1
  • acebilustat
  • Aerucin
  • alpha proteinase inhibitor (human) second generation
  • ALX09
  • amikacin sulphate
  • amlexanox
  • Anti-Pseudomonas IgY
  • Antimicrobial Drug for Cystic Fibrosis
  • AT10
  • ataluren
  • AZD634
  • BI43651
  • Biologics for Cystic Fibrosis Lung Infections
  • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis
  • Brevenal
  • Calcaftor
  • CFX
  • CSA3
  • CSY073
  • CT009
  • CTP56
  • cysteamine IR
  • dapsone
  • Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis
  • doripenem
  • dornase alfa biosimilar
  • dornase alfa biosimilar
  • Drugs for Cystic Fibrosis
  • FDL69
  • fenretinide
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR Gene for Cystic Fibrosis
  • GLPG837
  • GLPG837 + GLPG222 + GLPG665
  • GLPG222
  • GLPG451
  • GLPG665
  • GLPG737
  • GLPG851
  • glycerol phenylbutyrate
  • GSK225745
  • itraconazole
  • JBT01
  • kenpaullone
  • levofloxacin
  • levofloxacin
  • LJPC0Sa
  • LJPC0Sb
  • LMS11
  • LUNAR-CF
  • mannitol
  • MBN01
  • MG77
  • miglustat
  • MKA04
  • molgramostim
  • Mul867
  • N1115
  • N1138
  • N1169
  • nadolol
  • NB01
  • nitric oxide
  • nitric oxide
  • Nu
  • NVPQBE70
  • Oligomer G for Cystic Fibrosis
  • ORP00
  • P055
  • PAC-IC
  • Panaecin
  • PB1
  • PB046
  • PB120
  • PBI050
  • POL014
  • PRX10
  • PTI30
  • PTI28
  • PTIC811
  • PTIP71
  • PulmoXen
  • PXS728A
  • QR10
  • QRX
  • Recombinant A1PI
  • Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis
  • Recombinant Enzyme to Target DNA for Cystic Fibrosis
  • Recombinant Protein for Infectious Diseases and Respiratory Disorders
  • riociguat
  • RPL54
  • S226
  • S229
  • S8
  • seliciclib
  • SHP37
  • Small Molecule for Cystic Fibrosis
  • Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis
  • Small Molecule to Activate CFTR for Cystic Fibrosis
  • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD
  • Small Molecules for Bacterial Infections
  • Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis
  • Small Molecules for Cystic Fibrosis
  • Small Molecules to Activate CFTR for Cystic Fibrosis
  • Small Molecules to Activate CFTR Protein for Cystic Fibrosis
  • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis
  • Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis
  • Small Molecules to Block SCNN1 for Cystic Fibrosis
  • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis
  • Small Molecules to Inhibit USP8 for Cystic Fibrosis
  • sodium nitrite
  • solithromycin
  • SP4
  • SP
  • Stem Cell Therapy for Cystic Fibrosis
  • SYGN13
  • SYGN03
  • tritoqualine
  • vamorolone
  • vancomycin hydrochloride
  • VX52
  • VX71
  • VX40
  • ZP46

嚢胞性線維症:最近のパイプライン動向

嚢胞性線維症:休止中のプロジェクト

嚢胞性線維症:開発が中止された製品

嚢胞性線維症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7693IDB

Summary

Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H1 2016', provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
  • The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cystic Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Cystic Fibrosis - Overview
    • Pipeline Products for Cystic Fibrosis - Comparative Analysis
  • Cystic Fibrosis - Therapeutics under Development by Companies
  • Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Cystic Fibrosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cystic Fibrosis - Products under Development by Companies
  • Cystic Fibrosis - Products under Investigation by Universities/Institutes
  • Cystic Fibrosis - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Akari Therapeutics, Plc
    • Alaxia SAS
    • AlgiPharma AS
    • AmpliPhi Biosciences Corporation
    • Arcturus Therapeutics, Inc
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Calista Therapeutics, Inc.
    • Carolus Therapeutics, Inc.
    • Celtaxsys, Inc.
    • Chiesi Farmaceutici SpA
    • Cilian AG
    • Concert Pharmaceuticals, Inc.
    • Corbus pharmaceuticals, Inc.
    • CSA Biotechnologies LLC
    • Cyclacel Pharmaceuticals, Inc.
    • DiscoveryBiomed, Inc.
    • Editas Medicine, Inc.
    • Errant Gene Therapeutics, LLC
    • Galapagos NV
    • GlaxoSmithKline Plc
    • Grifols, S.A.
    • Grupo Praxis Pharmaceutical SA
    • Horizon Pharma Plc
    • Insmed Incorporated
    • Invion Limited
    • JHL Biotech, Inc.
    • Kamada Ltd.
    • La Jolla Pharmaceutical Company
    • Lamellar Biomedical Ltd
    • Laurent Pharmaceuticals Inc.
    • Mast Therapeutics, Inc.
    • Merck & Co., Inc.
    • Microbion Corporation
    • Mucokinetica Ltd.
    • NanoBio Corporation
    • Nivalis Therapeutics, Inc.
    • Nostrum Pharmaceuticals, LLC
    • Novabiotics Limited
    • Novartis AG
    • OSE Pharma SA
    • Parion Sciences, Inc.
    • Pfizer Inc.
    • Pharmaxis Limited
    • PhaseBio Pharmaceuticals, Inc.
    • Polyphor Ltd.
    • Progenra, Inc.
    • ProMetic Life Sciences Inc.
    • ProQR Therapeutics N.V.
    • Protalix BioTherapeutics, Inc.
    • Proteostasis Therapeutics, Inc.
    • PTC Therapeutics, Inc.
    • Pulmatrix, Inc.
    • Raptor Pharmaceutical Corp.
    • ReveraGen BioPharma, Inc.
    • Savara Inc.
    • Serendex Pharmaceuticals A/S
    • Shionogi & Co., Ltd.
    • Shire Plc
    • Synovo GmbH
    • TGV-Laboratories
    • The International Biotechnology Center (IBC) Generium
    • Verona Pharma Plc
    • Vertex Pharmaceuticals Incorporated
    • Xenetic Biosciences (UK) Limited
    • Zambon Company S.p.A.
  • Cystic Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ammonium chloride + citric acid + sodium citrate) - Drug Profile
    • (fosfomycin + tobramycin) - Drug Profile
    • (ivacaftor + tezacaftor) - Drug Profile
    • ABPA-01 - Drug Profile
    • acebilustat - Drug Profile
    • Aerucin - Drug Profile
    • alpha-1 proteinase inhibitor (human) second generation - Drug Profile
    • ALX-009 - Drug Profile
    • amikacin sulphate - Drug Profile
    • amlexanox - Drug Profile
    • Anti-Pseudomonas IgY - Drug Profile
    • Antimicrobial Drug for Cystic Fibrosis - Drug Profile
    • AT-010 - Drug Profile
    • ataluren - Drug Profile
    • AZD-5634 - Drug Profile
    • BI-443651 - Drug Profile
    • Biologics for Cystic Fibrosis Lung Infections - Drug Profile
    • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
    • Brevenal - Drug Profile
    • Calcaftor - Drug Profile
    • CFX-1 - Drug Profile
    • CSA-13 - Drug Profile
    • CSY-0073 - Drug Profile
    • CT-2009 - Drug Profile
    • CTP-656 - Drug Profile
    • cysteamine IR - Drug Profile
    • dapsone - Drug Profile
    • Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis - Drug Profile
    • doripenem - Drug Profile
    • dornase alfa biosimilar - Drug Profile
    • dornase alfa biosimilar - Drug Profile
    • Drugs for Cystic Fibrosis - Drug Profile
    • FDL-169 - Drug Profile
    • fenretinide - Drug Profile
    • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
    • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
    • Gene Therapy to Activate CFTR Gene for Cystic Fibrosis - Drug Profile
    • GLPG-1837 - Drug Profile
    • GLPG-1837 + GLPG-2222 + GLPG-2665 - Drug Profile
    • GLPG-2222 - Drug Profile
    • GLPG-2451 - Drug Profile
    • GLPG-2665 - Drug Profile
    • GLPG-2737 - Drug Profile
    • GLPG-2851 - Drug Profile
    • glycerol phenylbutyrate - Drug Profile
    • GSK-2225745 - Drug Profile
    • itraconazole - Drug Profile
    • JBT-101 - Drug Profile
    • kenpaullone - Drug Profile
    • levofloxacin - Drug Profile
    • levofloxacin - Drug Profile
    • LJPC-30Sa - Drug Profile
    • LJPC-30Sb - Drug Profile
    • LMS-611 - Drug Profile
    • LUNAR-CF - Drug Profile
    • mannitol - Drug Profile
    • MBN-101 - Drug Profile
    • MG-277 - Drug Profile
    • miglustat - Drug Profile
    • MKA-104 - Drug Profile
    • molgramostim - Drug Profile
    • Mul-1867 - Drug Profile
    • N-91115 - Drug Profile
    • N-91138 - Drug Profile
    • N-91169 - Drug Profile
    • nadolol - Drug Profile
    • NB-401 - Drug Profile
    • nitric oxide - Drug Profile
    • nitric oxide - Drug Profile
    • Nu-3 - Drug Profile
    • NVPQBE-170 - Drug Profile
    • Oligomer G for Cystic Fibrosis - Drug Profile
    • ORP-100 - Drug Profile
    • P-1055 - Drug Profile
    • PAC-IC - Drug Profile
    • Panaecin - Drug Profile
    • PB-01 - Drug Profile
    • PB-1046 - Drug Profile
    • PB-1120 - Drug Profile
    • PBI-4050 - Drug Profile
    • POL-6014 - Drug Profile
    • PRX-110 - Drug Profile
    • PTI-130 - Drug Profile
    • PTI-428 - Drug Profile
    • PTIC-1811 - Drug Profile
    • PTIP-271 - Drug Profile
    • PulmoXen - Drug Profile
    • PXS-4728A - Drug Profile
    • QR-010 - Drug Profile
    • QRX-4 - Drug Profile
    • Recombinant A1PI - Drug Profile
    • Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis - Drug Profile
    • Recombinant Enzyme to Target DNA for Cystic Fibrosis - Drug Profile
    • Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile
    • riociguat - Drug Profile
    • RPL-554 - Drug Profile
    • S-1226 - Drug Profile
    • S-1229 - Drug Profile
    • S-18 - Drug Profile
    • seliciclib - Drug Profile
    • SHP-637 - Drug Profile
    • Small Molecule for Cystic Fibrosis - Drug Profile
    • Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile
    • Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile
    • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
    • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile
    • Small Molecules for Cystic Fibrosis - Drug Profile
    • Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
    • Small Molecules to Activate CFTR Protein for Cystic Fibrosis - Drug Profile
    • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis - Drug Profile
    • Small Molecules to Block SCNN1 for Cystic Fibrosis - Drug Profile
    • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
    • Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile
    • sodium nitrite - Drug Profile
    • solithromycin - Drug Profile
    • SP-14 - Drug Profile
    • SP-9 - Drug Profile
    • Stem Cell Therapy for Cystic Fibrosis - Drug Profile
    • SYGN-113 - Drug Profile
    • SYGN-303 - Drug Profile
    • tritoqualine - Drug Profile
    • vamorolone - Drug Profile
    • vancomycin hydrochloride - Drug Profile
    • VX-152 - Drug Profile
    • VX-371 - Drug Profile
    • VX-440 - Drug Profile
    • ZP-046 - Drug Profile
  • Cystic Fibrosis - Recent Pipeline Updates
  • Cystic Fibrosis - Dormant Projects
  • Cystic Fibrosis - Discontinued Products
  • Cystic Fibrosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cystic Fibrosis, H1 2016
  • Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Cystic Fibrosis - Pipeline by Actelion Ltd, H1 2016
  • Cystic Fibrosis - Pipeline by Akari Therapeutics, Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Alaxia SAS, H1 2016
  • Cystic Fibrosis - Pipeline by AlgiPharma AS, H1 2016
  • Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H1 2016
  • Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc, H1 2016
  • Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H1 2016
  • Cystic Fibrosis - Pipeline by AstraZeneca Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Bayer AG, H1 2016
  • Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Cystic Fibrosis - Pipeline by Calista Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2016
  • Cystic Fibrosis - Pipeline by Cilian AG, H1 2016
  • Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by CSA Biotechnologies LLC , H1 2016
  • Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Editas Medicine, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H1 2016
  • Cystic Fibrosis - Pipeline by Galapagos NV, H1 2016
  • Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Grifols, S.A., H1 2016
  • Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2016
  • Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Insmed Incorporated, H1 2016
  • Cystic Fibrosis - Pipeline by Invion Limited, H1 2016
  • Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Kamada Ltd., H1 2016
  • Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H1 2016
  • Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H1 2016
  • Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Merck & Co., Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Microbion Corporation, H1 2016
  • Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H1 2016
  • Cystic Fibrosis - Pipeline by NanoBio Corporation, H1 2016
  • Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016
  • Cystic Fibrosis - Pipeline by Novabiotics Limited, H1 2016
  • Cystic Fibrosis - Pipeline by Novartis AG, H1 2016
  • Cystic Fibrosis - Pipeline by OSE Pharma SA, H1 2016
  • Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Pfizer Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Pharmaxis Limited, H1 2016
  • Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Polyphor Ltd., H1 2016
  • Cystic Fibrosis - Pipeline by Progenra, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H1 2016
  • Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H1 2016
  • Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Savara Inc., H1 2016
  • Cystic Fibrosis - Pipeline by Serendex Pharmaceuticals A/S, H1 2016
  • Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Cystic Fibrosis - Pipeline by Shire Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Synovo GmbH, H1 2016
  • Cystic Fibrosis - Pipeline by TGV-Laboratories, H1 2016
  • Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Cystic Fibrosis - Pipeline by Verona Pharma Plc, H1 2016
  • Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Cystic Fibrosis - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Cystic Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Cystic Fibrosis - Dormant Projects, H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..1), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..2), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..3), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..4), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..5), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..6), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..7), H1 2016
  • Cystic Fibrosis - Dormant Projects (Contd..8), H1 2016
  • Cystic Fibrosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Cystic Fibrosis, H1 2016
  • Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top